Robinson E N
Department of Medicine, University of North Carolina School of Medicine, Greensboro.
Clin Infect Dis. 1993 Mar;16(3):357-60. doi: 10.1093/clind/16.3.357.
Following the paradigm of the hospitals of the National Institutes of Health and the University of California at San Francisco, many medical facilities have instituted a policy of administering zidovudine to health care workers after exposure to blood potentially contaminated with the human immunodeficiency virus. There is no clinical evidence proving the efficacy of such chemoprophylaxis. Toxic effects associated with zidovudine are usual and at times severe. The institutional administration of zidovudine to anyone other than individuals infected with the human immunodeficiency virus should be discontinued except under the auspices of a randomized, placebo-controlled trial.
遵循美国国立卫生研究院和加利福尼亚大学旧金山分校医院的模式，许多医疗设施已制定一项政策，即在医护人员接触可能被人类免疫缺陷病毒污染的血液后，给予其齐多夫定。没有临床证据证明这种化学预防的有效性。与齐多夫定相关的毒性作用很常见，有时还很严重。除了在随机、安慰剂对照试验的主持下，应停止对除感染人类免疫缺陷病毒的个体以外的任何人进行齐多夫定的机构给药。
